Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDG-15400 in Healthy Adults
NCT07177066Phase 1Completed
- Start
- Aug 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EDG-15400 (3 arms). Primary endpoint: Treatment-Emergent Adverse Events at 45 days. Started Aug 2025; status: completed.
02
Drugs
EDG-15400
Beyond the preview
Go deeper on NCT07177066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07177066.